$8.56 Million in Sales Expected for OptiNose Inc (NASDAQ:OPTN) This Quarter

Equities analysts expect that OptiNose Inc (NASDAQ:OPTN) will report $8.56 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for OptiNose’s earnings. The highest sales estimate is $8.61 million and the lowest is $8.50 million. OptiNose reported sales of $1.90 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 350.5%. The company is scheduled to announce its next earnings report on Tuesday, November 12th.

On average, analysts expect that OptiNose will report full-year sales of $32.45 million for the current financial year, with estimates ranging from $32.10 million to $32.79 million. For the next fiscal year, analysts expect that the firm will post sales of $84.08 million, with estimates ranging from $77.80 million to $90.35 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for OptiNose.

OptiNose (NASDAQ:OPTN) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. The company had revenue of $6.68 million for the quarter, compared to the consensus estimate of $7.74 million. OptiNose had a negative net margin of 670.20% and a negative return on equity of 102.10%.

OPTN has been the topic of a number of recent analyst reports. ValuEngine upgraded shares of OptiNose from a “hold” rating to a “buy” rating in a research note on Thursday, October 3rd. Royal Bank of Canada set a $20.00 target price on shares of OptiNose and gave the stock a “buy” rating in a research note on Monday, August 12th. BMO Capital Markets decreased their target price on shares of OptiNose from $26.00 to $24.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Finally, Zacks Investment Research cut shares of OptiNose from a “hold” rating to a “sell” rating in a research note on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $21.50.

OPTN opened at $7.90 on Wednesday. OptiNose has a 12-month low of $4.44 and a 12-month high of $12.05. The company has a market cap of $309.11 million, a price-to-earnings ratio of -2.95 and a beta of 0.58. The company’s 50 day moving average is $7.21 and its 200 day moving average is $7.57. The company has a current ratio of 6.60, a quick ratio of 6.43 and a debt-to-equity ratio of 1.06.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp raised its stake in OptiNose by 0.8% during the 2nd quarter. Northern Trust Corp now owns 227,704 shares of the company’s stock worth $1,611,000 after acquiring an additional 1,797 shares during the period. Bank of America Corp DE raised its stake in OptiNose by 8.1% during the 2nd quarter. Bank of America Corp DE now owns 105,689 shares of the company’s stock worth $748,000 after acquiring an additional 7,944 shares during the period. Swiss National Bank raised its stake in OptiNose by 36.4% during the 2nd quarter. Swiss National Bank now owns 30,700 shares of the company’s stock worth $217,000 after acquiring an additional 8,200 shares during the period. Bank of New York Mellon Corp raised its stake in OptiNose by 6.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 155,873 shares of the company’s stock worth $1,104,000 after acquiring an additional 9,516 shares during the period. Finally, UBS Asset Management Americas Inc. bought a new stake in OptiNose during the 2nd quarter worth approximately $72,000. Institutional investors own 64.98% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Further Reading: What is Considered a Good Return on Equity (ROE)?

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.